Greater monoamine oxidase a binding in perimenopausal age as measured with carbon 11-labeled harmine positron emission tomography

JAMA Psychiatry

Volumn 71, Issue 8, 2014, Pages 873-879

  Rekkas, Paraskevi Vivien ^a   Wilson, Alan A ^a   Lee, Vivian Wai Han ^a   Yogalingam, Priyanga ^a   Sacher, Julia ^b   Rusjan, Pablo ^a   Houle, Sylvain ^a   Stewart, Donna E ^a   Kolla, Nathan J ^a   Kish, Stephen ^a   Chiuccariello, Lina ^a   Meyer, Jeffrey H ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); BIOLOGICAL MARKER; CARBON; HARMINE; MONOAMINE OXIDASE INHIBITOR; PROTEIN BINDING;

ADULT; BRAIN; CLIMACTERIUM; CROSS-SECTIONAL STUDY; DIAGNOSTIC USE; ENZYMOLOGY; FEMALE; HUMAN; MAJOR DEPRESSION; MENSTRUAL CYCLE; METABOLISM; MIDDLE AGED; PHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PROCEDURES;

ADULT; BIOLOGICAL MARKERS; BRAIN; CARBON RADIOISOTOPES; CROSS-SECTIONAL STUDIES; DEPRESSIVE DISORDER, MAJOR; FEMALE; HARMINE; HUMANS; MENSTRUAL CYCLE; MIDDLE AGED; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; PERIMENOPAUSE; POSITRON-EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PROTEIN BINDING;

EID: 84905825488     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2014.250     Document Type: Article

References (56)

1. Speroff L, Fritz M. Clinical Gynecologic Endocrinology and Infertility. 7th ed. Philadelphia, PA: LippincottWilliams &Wilkins; 2005.
2. Cohen LS, Soares CN, Vitonis AF, OttoMW, Harlow BL. Risk for new onset of depression during the menopausal transition: the Harvard study of moods and cycles. Arch Gen Psychiatry. 2006;63 (4): 385-390.
3. Freeman EW, Sammel MD, Lin H, Nelson DB. Associations of hormones and menopausal status with depressed mood in women with no history of depression. Arch Gen Psychiatry. 2006;63(4): 375-382.
4. McClure RE, Barha CK, Galea LA. 17β-Estradiol, but not estrone, increases the survival and activation of new neurons in the hippocampus in response to spatial memory in adult female rats. Horm Behav. 2013;63(1): 144-157.
5. McEwen BS, Akama KT, Spencer-Segal JL,Milner TA,Waters EM. Estrogen effects on the brain: actions beyond the hypothalamus via novel mechanisms. Behav Neurosci. 2012;126(1): 4-16.
6. Benmansour S,Weaver RS, Barton AK, Adeniji OS, Frazer A. Comparison of the effects of estradiol and progesterone on serotonergic function. Biol Psychiatry. 2012;71(7): 633-641.
7. Morissette M, Al Sweidi S, Callier S, Di Paolo T. Estrogen and SERM neuroprotection in animal models of Parkinson's disease. Mol Cell Endocrinol. 2008;290(1-2): 60-69.
8. Ou XM, Chen K, Shih JC. Monoamine oxidase A and repressor R1 are involved in apoptotic signaling pathway. Proc Natl Acad Sci U S A. 2006;103(29): 10923-10928.
9. Fitzgerald JC, Ufer C, De Girolamo LA, Kuhn H, Billett EE. Monoamine oxidase-A modulates apoptotic cell death induced by staurosporine in human neuroblastoma cells. J Neurochem. 2007; 103(6): 2189-2199.
10. Luine VN, McEwen BS. Effect of oestradiol on turnover of type A monoamine oxidase in brain. J Neurochem. 1977;28(6): 1221-1227.
11. Holschneider DP, Kumazawa T, Chen K, Shih JC. Tissue-specific effects of estrogen on monoamine oxidase A and B in the rat. Life Sci. 1998;63(3): 155-160.
12. Gundlah C, Lu NZ, Bethea CL. Ovarian steroid regulation of monoamine oxidase-A and-B mRNAs in the macaque dorsal raphe and hypothalamic nuclei. Psychopharmacology (Berl). 2002;160(3): 271-282.
13. Smith LJ, Henderson JA, Abell CW, Bethea CL. Effects of ovarian steroids and raloxifene on proteins that synthesize, transport, and degrade serotonin in the raphe region of macaques. Neuropsychopharmacology. 2004;29(11): 2035-2045.
14. Ma ZQ, Violani E, Villa F, Picotti GB, Maggi A. Estrogenic control of monoamine oxidase A activity in human neuroblastoma cells expressing physiological concentrations of estrogen receptor. Eur J Pharmacol. 1995;284(1-2): 171-176.
15. Son SY,Ma J, Kondou Y, YoshimuraM, Yamashita E, Tsukihara T. Structure of human monoamine oxidase A at 2.2-A resolution: the control of opening the entry for substrates/inhibitors. Proc Natl Acad Sci U S A. 2008;105(15): 5739-5744.
16. BergströmM,Westerberg G, Långström B. 11C-harmine as a tracer for monoamine oxidase A (MAO-A): in vitro and in vivo studies. Nucl Med Biol. 1997;24(4): 287-293.
17. Ginovart N,Meyer JH, Boovariwala A, et al. Positron emission tomography quantification of [11C]-harmine binding to monoamine oxidase-A in the human brain. J Cereb Blood Flow Metab. 2006; 26(3): 330-344.
18. Tong J,Meyer JH, Furukawa Y, et al. Distribution of monoamine oxidase proteins in human brain: implications for brain imaging studies. J Cereb Blood Flow Metab. 2013;33(6): 863-871.
19. Grigoriou V, Augoulea A, Armeni E, et al. Prevalence of vasomotor, psychological, psychosomatic and sexual symptoms in perimenopausal and recently postmenopausal Greek women: association with demographic, life-style and hormonal factors. Gynecol Endocrinol. 2013;29(2): 125-128.
20. Greene JG. Constructing a standard climacteric scale. Maturitas. 2008;61(1-2): 78-84.
21. Sacher J, Wilson AA, Houle S, et al. Elevated brain monoamine oxidase A binding in the early postpartum period. Arch Gen Psychiatry. 2010;67 (5): 468-474.
22. Gale S, Harlow BL. Postpartum mood disorders: a review of clinical and epidemiological factors. J Psychosom Obstet Gynaecol. 2003;24(4): 257-266.
23. Soules MR, Sherman S, Parrott E, et al. Executive summary: Stages of Reproductive Aging Workshop (STRAW). Fertil Steril. 2001;76(5): 874-878.
24. HamiltonM. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1): 56-62.
25. FirstM, Spitzer R, Williams J, Gibbon M. Structured Clinical Interview for DSM-IV, Non-Patient Edition (SCID-NP, Version 1.0). Washington, DC: American Psychiatric Press; 1995.
26. FirstM, Gibbon M, Spitzer RL,Williams JBW, Benjamin LS. Structured Clinical Interview for DSM-IV Axis II Personality Disorders.Washington, DC: American Psychiatric Publishing; 1997.
27. Vingerhoets AJJM. Adult Crying Questionnaire. In: Vingerhoets AJJM, Cornelius RR, eds. Adult Crying: A Biopsychological Approach. New York, NY: Taylor & Francis; 2001: 303.
28. Scheirs GM, Sijtsma K. The study of crying: some methodological considerations and a comparison ofmethods for analyzing questionnaires. In: Vingerhoets AJJM, Cornelius RR, eds. Adult Crying: A Biopsychological Approach. New York, NY: Taylor & Francis; 2001: 277-298.
29. Van Tilberg MAL, UnterbergML, Vingerhoets AJJM. Crying during adolescence: the role of gender, menarche and empathy. Br J Dev Psychol. 2002;20(1): 77-87. doi: 10.1348/026151002166334.
30. Peter M, Vingerhoets AJJM, Van Heck GL. Personality, gender and crying. Eur J Pers. 2001;15 (1): 19-28. doi: 10.1002/per.386.
31. Hauser GA, Huber IC, Keller PJ, Lauritzen C, Schneider HPG. Evaluation of climacteric symptoms (Menopause Rating Scale) [in German]. Zentralbl Gynakol. 1994;116(1): 16-23.
32. Rusjan P, Mamo D, Ginovart N, et al. An automated method for the extraction of regional data from PET images. Psychiatry Res. 2006;147(1): 79-89.
33. Chiuccariello L, Houle S,Miler L, et al. Elevated monoamine oxidase a binding during major depressive episodes is associated with greater severity and reversed neurovegetative symptoms. Neuropsychopharmacology. 2014;39(4): 973-980.
34. Ressler KJ,Mayberg HS. Targeting abnormal neural circuits in mood and anxiety disorders: from the laboratory to the clinic. Nat Neurosci. 2007;10 (9): 1116-1124.
35. Saura J, Bleuel Z, Ulrich J, et al. Molecular neuroanatomy of human monoamine oxidases A and B revealed by quantitative enzyme radioautography and in situ hybridization histochemistry. Neuroscience. 1996;70(3): 755-774.
36. Meyer JH, Ginovart N, Boovariwala A, et al. Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression. Arch Gen Psychiatry. 2006;63 (11): 1209-1216.
37. Meyer JH, Wilson AA, Sagrati S, et al. Brain monoamine oxidase A binding in major depressive disorder: relationship to selective serotonin reuptake inhibitor treatment, recovery, and recurrence. Arch Gen Psychiatry. 2009;66(12): 1304-1312.
38. Johnson S, Stockmeier CA,Meyer JH, et al. The reduction of R1, a novel repressor protein for monoamine oxidase A, in major depressive disorder. Neuropsychopharmacology. 2011;36(10): 2139-2148.
39. FilipenkoML, Beilina AG, Alekseyenko OV, Dolgov VV, Kudryavtseva NN. Increase in expression of brain serotonin transporter and monoamine oxidase a genes induced by repeated experience of social defeats in malemice. Biochemistry (Mosc). 2002;67(4): 451-455.
40. Yu Y,Wang R, Chen C, et al. Antidepressant-like effect of trans-resveratrol in chronic stress model: behavioral and neurochemical evidences. J Psychiatr Res. 2013;47(3): 315-322.
41. GrunewaldM, Johnson S, Lu D, et al. Mechanistic role for a novel glucocorticoid-KLF11 (TIEG2) protein pathway in stress-induced monoamine oxidase A expression. J Biol Chem. 2012;287(29): 24195-24206.
42. Moses-Kolko EL, Price JC, Shah N, et al. Age, sex, and reproductive hormone effects on brain serotonin-1A and serotonin-2A receptor binding in a healthy population. Neuropsychopharmacology. 2011;36(13): 2729-2740.
43. Youdim MBH, Edmondson D, Tipton KF. The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci. 2006;7(4): 295-309.
44. Yan MH,Wang X, Zhu X. Mitochondrial defects and oxidative stress in Alzheimer disease and Parkinson disease. Free Radic Biol Med. 2013;62: 90-101.
45. BurkeWJ, Li SW, Chung HD, et al. Neurotoxicity of MAOmetabolites of catecholamine neurotransmitters: role in neurodegenerative diseases. Neurotoxicology. 2004;25(1-2): 101-115.
46. Scott E, Zhang QG,Wang R, Vadlamudi R, Brann D. Estrogen neuroprotection and the critical period hypothesis. Front Neuroendocrinol. 2012; 33(1): 85-104.
47. Brinton RD. The healthy cell bias of estrogen action: mitochondrial bioenergetics and neurological implications. Trends Neurosci. 2008;31 (10): 529-537.
48. Resnick SM, Espeland MA, Jaramillo SA, et al. Postmenopausal hormone therapy and regional brain volumes: the WHIMS-MRI Study. Neurology. 2009;72(2): 135-142.
49. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al; WHI Investigators. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA. 2003;289(20): 2673-2684.
50. Holschneider DP, Chen K, Seif I, Shih JC. Biochemical, behavioral, physiologic, and neurodevelopmental changes inmice deficient in monoamine oxidase A or B. Brain Res Bull. 2001;56 (5): 453-462.
51. Bortolato M, Chen K, Shih JC. Monoamine oxidase inactivation: from pathophysiology to therapeutics. Adv Drug Deliv Rev. 2008;60(13-14): 1527-1533.
52. Meyer JH. Neuroimaging markers of cellular function in major depressive disorder: implications for therapeutics, personalized medicine, and prevention. Clin Pharmacol Ther. 2012;91(2): 201-214.
53. Fowler CJ, Wiberg A, Oreland L, Marcusson J, Winblad B. The effect of age on the activity and molecular properties of human brain monoamine oxidase. J Neural Transm. 1980;49(1-2): 1-20.
54. Galva MD, Bondiolotti GP, Olasmaa M, Picotti GB. Effect of aging on lazabemide binding, monoamine oxidase activity and monoamine metabolites in human frontal cortex. J Neural Transm Gen Sect. 1995;101(1-3): 83-94.
55. Kornhuber J, Konradi C, Mack-Burkhardt F, Riederer P, Heinsen H, Beckmann H. Ontogenesis of monoamine oxidase-A and-B in the human brain frontal cortex. Brain Res. 1989;499(1): 81-86.
56. Sacher J, Houle S, Parkes J, et al. Monoamine oxidase A inhibitor occupancy during treatment of major depressive episodes with moclobemide or St. John'swort: an [11C]-harmine PET study. J Psychiatry Neurosci. 2011;36(6): 375-382.